<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" xml:lang="EN">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title>Emerging Infectious Diseases</journal-title>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18976579</article-id>
      <article-id pub-id-type="pmc">2630745</article-id>
      <article-id pub-id-type="publisher-id">08-0517</article-id>
      <article-id pub-id-type="doi">10.3201/eid1411.080517</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Paralysis Case and Contact Spread of Recombinant Vaccine&#x2013;derived Poliovirus, Spain</article-title>
        <alt-title alt-title-type="running-head">Paralysis Case and Contact Spread of Recombinant Vaccine&#x2013;derived Poliovirus, Spain</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Avell&#xF3;n</surname>
            <given-names>Ana</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cabrerizo</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Miguel</surname>
            <given-names>Teresa</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>P&#xE9;rez-Bre&#xF1;a</surname>
            <given-names>Pilar</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tenorio</surname>
            <given-names>Antonio</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>P&#xE9;rez</surname>
            <given-names>Jose Luis</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mart&#xED;nez de Arag&#xF3;n</surname>
            <given-names>Maria Victoria</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Trallero</surname>
            <given-names>Gloria</given-names>
          </name>
        </contrib>
        <aff id="aff1"><label>1</label>These authors contributed equally to this article.</aff>
        <aff id="aff2">Instituto de Salud Carlos III National Centre of Microbiology, Madrid, Spain (A. Avell&#xF3;n, M. Cabrerizo, T. de Miguel, P. P&#xE9;rez-Bre&#xF1;a, A. Tenorio, G. Trallero)</aff>
        <aff id="aff3">Instituto de Salud Carlos III National Centre of Epidemiology, Madrid (M.V. Mart&#xED;nez de Arag&#xF3;n)</aff>
        <aff id="aff4">Son Dureta Hospital, Palma de Mallorca, Spain (J.L. P&#xE9;rez)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Ana Avellon, National Centre of Microbiology &#x2013; Diagnostic Microbiology Service, Carretera Majadahonda-Pozuelo Km.2, Majadahonda, Madrid 28220, Spain; email: <email xlink:href="aavellon@isciii.es">aavellon@isciii.es</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2008</year>
      </pub-date>
      <volume>14</volume>
      <issue>11</issue>
      <fpage>1807</fpage>
      <lpage>1809</lpage>
      <kwd-group kwd-group-type="author" xml:lang="EN">
        <title>Keywords: </title>
        <kwd>poliovirus</kwd>
        <kwd>poliomyelitis</kwd>
        <kwd>enterovirus</kwd>
        <kwd>VDPV</kwd>
        <kwd>letter</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> The World Health Organization Polio Eradication Initiative has reduced to 4 the number of countries with endemic transmission of wild polioviruses and has reported the widespread circulation of polioviruses that have evolved from attenuated vaccine (oral poliovirus vaccine [OPV]), so-called vaccine-derived polioviruses (VDPVs) (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>,<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). VDPVs can reportedly replicate in immunocompromised persons, in whom they produce paralysis, and can spread to contacts and produce paralytic polio in immunocompetent but incompletely immunized persons; these viruses can even cause some polio outbreaks in areas with a low level of vaccination coverage (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). When VDPVs are detected, a careful follow-up of VDPV cases and contacts is essential if spread is to be avoided. Because point mutations or recombination events have been associated with reversion to neurovirulence transmission and thus a greater probability of outbreaks (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>), meticulous molecular studies of the detected strains are recommended.</p>
    <p>Spain progressively adopted vaccination with OPV for children in 2004. As a consequence, the incidence of vaccine-like poliovirus detection in recently vaccinated children, which was relatively common up to that time (51 isolates in 2003) (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>), began to decrease (15 isolates in 2004 and none in 2005 except the case described here). In July 2005, a 14-month-old boy from Morocco with residual paralysis and major histocompatibility class II immunodeficiency was reported through the Spanish Acute Flaccid Paralysis Surveillance System. The patient had received 2 OPV doses at birth and at 6 months of age in Morocco; 8 months later, meningoencephalitis developed. The case was immediately considered suspicious and was therefore monitored at least monthly until the boy died. Sampling was conducted, coinciding with his visits to the hospital to receive therapy with immunoglobulin (&#x3B3; globulin 0.5 g/kg). His contacts were studied, environmental surveillance was conducted, and molecular analysis of all detected viruses was performed. Laboratory methods for virus detection and characterization, including 10 new reverse-transcription&#x2013;PCRs designed to cover the entire genome, are detailed in the <xref ref-type="table" rid="T1">Table</xref>.</p>
    <table-wrap id="T1" position="float">
      <label>Table</label>
      <caption>
        <title>Laboratory methods used for study of vaccine-derived poliovirus case, Spain, 2005*</title>
      </caption>
      <table frame="hsides" rules="groups">
        <col width="50" span="1"/>
        <col width="156" span="1"/>
        <col width="239" span="1"/>
        <col width="35" span="1"/>
        <thead>
          <tr>
            <th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><font color="ALLCAPS">p</font>rocedure</th>
            <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Test</th>
            <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Method&#x2020;</th>
            <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Sample</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Sample preparation<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Concentration of sewage for detection of enterovirus in the environment</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Concentration with negative charge filters (Millipore, Billerica, MA, USA; 0.45 &#x3BC;m) of 20 L of local sewage</td>
            <td valign="top" align="center" rowspan="1" colspan="1">E</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">RNA purification from samples (before molecular analysis)<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">MagAttract Virus Mini-Biorobot (QIAGEN GmbH, Hilden, Germany) from 200 &#x3BC;L of stool sample dissolved in water<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">S<hr/></td>
          </tr>
          <tr>
            <td rowspan="3" valign="top" align="left" scope="row" colspan="1">Classic virology techniques<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Cellular culture (Biosafety Level 3) for growing PV</td>
            <td valign="top" align="center" rowspan="1" colspan="1">LB20 (transgenic mouse), RD (human rhabdomyosarcoma), HEF (human fibroblast), A-549 (ATCC-CCL185)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, E</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">Immunofluorescence of infected cells</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Lim-Beyesh-Melnick A-H and RIVM A-G pools</td>
            <td valign="top" align="center" rowspan="1" colspan="1">I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">EV neutralization assay<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Antibodies (Chemicon, Temecula, CA, USA)<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">I<hr/></td>
          </tr>
          <tr>
            <td rowspan="15" valign="top" align="left" scope="row" colspan="1">Molecular techniques</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Molecular EV detection</td>
            <td valign="top" align="center" rowspan="1" colspan="1">RT-nested PCR 5&#x2032; UTR (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I, E</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">Molecular EV quantification</td>
            <td valign="top" align="center" rowspan="1" colspan="1">MutaReal EV real-time PCR kit (Immunodiagnostik AG, Bensheim, Germany)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">Molecular EV typing</td>
            <td valign="top" align="center" rowspan="1" colspan="1">RT-nested PCR in major VP1 region (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I, E</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV intratypic characterization</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Specific vaccine PV RT-PCR (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I, E</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 1</td>
            <td valign="top" align="center" rowspan="1" colspan="1">1s: TAAAACAGCTCTGGGGTTGTA (2&#x2013;22)&#x2028;1as: CACCACCCAAGAAGCGGCC (1023&#x2013;1041)&#x2028;1ns: GCTCTGGGGTTGTACCCACTCC (9&#x2013;30)&#x2028;1nas:TAACTCTGGGCAATTCAACGA(1001&#x2013;1021)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 2&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">2s: CATGCTAAACTCCCCAAAC (945&#x2013;963)&#x2028;2as: AGGTGCGCAACATGATGG (1882&#x2013;1910)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 3&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">3s: CAGACAATTACCAGTCTCC (1814&#x2013;1832)&#x2028;3as: ATTACTAAAAATGCATTGGTTCCC (2518&#x2013;2541)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing VP1 fragment&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">VP1s: ACAACACACATTAGTCAAGAGGCTA (2449&#x2013;2473)&#x2028;VP1as: GGATTTGGACACCAAAACAAAGC (3385&#x2013;3407)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 4&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">4s:GTGCCCACGACCTCCA (3288&#x2013;3303)&#x2028;4as: CTTGGGTGCGACATCTCA (4042&#x2013;4059)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 5&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">5s: TAATCAAAATTATCTCATCACTTGTG (3962&#x2013;3987)&#x2028;5as: CATGAGCGAGTACTCCAGA (4872&#x2013;4889)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 6&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">6s: CTGGCCAGGAGATTCG (4834&#x2013;4949)&#x2028;6as: AAATGATGGAGTTTTGATCGT(5725&#x2013;5747)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 7&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">7s: AGGCAGGAACTAATCTTGAAA (5630&#x2013;5650)&#x2028;7as: CTAAGTATGTAGGCAACAAGAT (6164&#x2013;6185)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 8&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">8s: CAAAAATGATCCCAGGCTCA (6117&#x2013;6136)&#x2028;8as: AAACCTACAAGGGCATAGATT (6917&#x2013;6937)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">PV genome sequencing fragment 9&#x2020;</td>
            <td valign="top" align="center" rowspan="1" colspan="1">9s: CAGGCACATCAATTTTTAACTC (6857&#x2013;6878)&#x2028;9as: GGTAAATTTTTCTTTAATTCGGGG(7416&#x2013;7439)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
          <tr>
            <td valign="top" colspan="1" align="center" scope="row" rowspan="1">Additional PV sequencing primers</td>
            <td valign="top" align="center" rowspan="1" colspan="1">447as: CCGGCCCCTGAATGCGGC (447&#x2013;464)&#x2028;4666s: CCAGACGGAGCAGACATG (4666&#x2013;4683)</td>
            <td valign="top" align="center" rowspan="1" colspan="1">S, I</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <p>*E, local sewage; S, stools; I, isolates; EV, enterovirus; PV, poliovirus; UTR, untranslated region; VP1, virus capsid protein.&#x2028;&#x2020;Sense (s) and antisense (as) primers: 5&#x2032; &#x2192; 3' sequence (position according to X00595). n, nested. All reverse transcription&#x2013;PCR (RT-PCR) systems had the same conditions: 5 &#x3BC;L of clinical samples (case) or isolates (contacts) were added to the reaction mixture (final volume 50 &#x3BC;L): AMV/Tfl 1X reaction buffer, 2 mmol/L MgSO<sub>4</sub>, 200 &#x3BC;M each dNTP, 1 &#x3BC;M each primer, 5 U of AMV RT, and 5 U of Tfl DNA polymerase (Access RT-PCR System, Promega, Madison, WI, USA). First RT step of 45 min at 48&#xB0;C, 2 min at 94&#xB0;C, 45 cycles of denaturation (94&#xB0;C, 2 min), annealing (53&#xB0;C, 1 min), and elongation (68&#xB0;C,1 min 30 s).</p>
      </table-wrap-foot>
    </table-wrap>
    <p>Serotype 2 VDPVs were detected in all 10 stool samples of the patient with residual paralysis for 6 months, until he died, and in 3 of the 7 family contacts analyzed (father and 2 brothers, 11 and 13 years of age, none with confirmed previous vaccination). One of the contacts, considered immunocompetent, shed virus for 216 days (5 fecal samples in which 5 complete genomes were obtained and 1 additional fecal sample in which virus capsid protein l [VP1] could be amplified); a stool sample collected on day 284 was negative. Technical problems delayed sewage sampling. When sewage from the area in which the patient and positive contacts lived was sampled on February 8, 2006, no polioviruses were detected; however, an echovirus 30 was detected. Poliovirus viral load fluctuated (10<sup>6</sup>&#x2013;10<sup>9</sup> copies/mL in the paralysis-affected person), decreasing after each immunoglobulin therapy dose (Figure 1 in the <xref ref-type="local-data" rid="SD1">Technical Appendix</xref>). The corresponding level was &lt;10<sup>5</sup> in the contacts. The highest value of viral load was recorded in the patient&#x2019;s final sample, taken before he died. Homology of the VP1 gene with respect to the original vaccine PV2 fluctuated from 97.8% to 98.6% in the case samples but remained constant (98.4%) in the contact samples (Figure 1 in the <xref ref-type="local-data" rid="SD1">Technical Appendix</xref>). All studied polioviruses featured the following nucleotide substitutions in the 5&#x2032; untranslated region: G309A, T344C, T355C, T398C, A481G, T500C, and T743C (Figure 2 in the <xref ref-type="local-data" rid="SD1">Technical Appendix</xref>). Furthermore, the final sample from the patient had A476C, G505T, T588A, and A738C. Several nucleotide substitutions detected in VP1&#x2013;4 were common to all samples (Figure 2 in the <xref ref-type="local-data" rid="SD1">Technical Appendix</xref>); 5 resulted in amino acid changes, including T2909C (VP1 I143T) and G3277A (VP1 V266I). All samples contained 2 noncontiguous recombination fragments Sabin 2/Sabin 1 in the nonstructural genes, including the entire 3C gene and the 3&#x2032; half of the 3D-pol (Figure 2 in the <xref ref-type="local-data" rid="SD1">Technical Appendix</xref>) as in other reports (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>&#x2013;<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>). Both fragments, when compared with C species enterovirus, were closely related to Sabin 1 (99.6% and 97.9%, respectively). Specific nucleotide and amino acid comparisons among the isolates are detailed in Figure 3 in the <xref ref-type="local-data" rid="SD1">Technical Appendix</xref>.</p>
    <p>According to the proposed classification (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>), all the detected viruses were iVDPVs (isolated from immunocompromised patients) that spread only to close contacts because they were not detected in local sewage. If we assume that the greater the amount of viral excretion in feces that occurs, the higher number of replicating polioviruses (as well as the potential for greater genetic diversity), the patient had a more active infection (that responded to the therapy) than did the contacts. Fluctuation in homology to the parental OPV strain might be due not only to the calculation method (calculation was made on the basis of the majority-base call at each chromatogram position, and case sequences presented many mixed nucleotide positions) but also to immunotherapy. Treatment appeared to have decreased virus replication, probably by its action mainly on species with greater fitness and higher replication rates (those that were more similar to the original Sabin strain). As a consequence, treatment might produce a bottleneck that unmasked more divergent species. Both the case and contact strains had intertypic Sabin 1/Sabin 2 recombination in nonstructural genes and also shared most of the nucleotide and amino acid substitutions. However, pathologic changes occurred only in the patient whose immunologic mechanisms were affected and whose viral load was consequently much higher. A recent report (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>) suggests that VDPVs can emerge in any country that uses OPV with insufficient vaccine coverage. In a polio-free IPV-user country, poliomyelitis can arise and spread to contacts who are not properly vaccinated. In the case we present here, the high level of vaccination coverage in Spain and the rapid control of close contacts achieved through the surveillance and control programs prevented virus spread. In the global pre-eradication phase, countries are recommended to change vaccination from OPV to IPV. However, IPV-adopting countries commonly share borders with OPV-adopting countries and residents may travel back and forth; thus, although the probability of VDPV circulation decreases, it does not reduce to zero. Therefore, active surveillance, rapid classification of isolates, and molecular characterization of the virus are essential.</p>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <caption>
          <title>Technical Appendix</title>
          <p>Paralysis Case and Contact Spread of Recombinant Vaccine-derived Poliovirus, Spain</p>
        </caption>
        <media xlink:href="08-0517_Techapp-s1.pdf" xlink:type="simple" id="N0x1c871b0N0x3574d80" position="anchor" mimetype="application" mime-subtype="pdf"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Avell&#xF3;n A, Cabrerizo M, de Miguel T, P&#xE9;rez-Bre&#xF1;a P, Tenorio A, P&#xE9;rez JL, et al. Paralysis case and contact spread of recombinant vaccine&#x2013;derived poliovirus, Spain [letter]. Emerg Infect Dis [serial on the Internet]. Nov 2008 [<italic>date cited</italic>]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/EID/content/14/11/1807.htm">http://www.cdc.gov/EID/content/14/11/1807.htm</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank the Spanish Poliovirus Surveillance system, in which both the National Epidemiology and Microbiology Centres and autonomous community authorities participate, for detecting the case; the personnel of the National Centre of Microbiology and Son Dureta Hospital for their technical assistance; and Jose Manuel Echevarria for revision of our manuscript.</p>
      <p>This research was developed thanks to the Health Minister DGVI1429/05-2A and 2B funding.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <citation citation-type="journal"><string-name><surname>Dowdle</surname> <given-names>W</given-names></string-name>, <string-name><surname>Kew</surname> <given-names>O</given-names></string-name> <article-title>Vaccine-derived polioviruses: is it time to stop using the word &#x201C;rare&#x201D;?</article-title><source>J Infect Dis</source> <year>2006</year>;<volume>194</volume>:<fpage>539</fpage>&#x2013;<lpage>41</lpage> <pub-id pub-id-type="doi">10.1086/506368</pub-id><pub-id pub-id-type="pmid">16897648</pub-id></citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <citation citation-type="journal"><string-name><surname>Kew</surname> <given-names>OM</given-names></string-name>, <string-name><surname>Sutter</surname> <given-names>RW</given-names></string-name>, <string-name><surname>de Gourville</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Dowdle</surname> <given-names>WR</given-names></string-name>, <string-name><surname>Pallansch</surname> <given-names>MA</given-names></string-name> <article-title>Vaccine-derived polioviruses and the endgame strategy for global polio eradication.</article-title><source>Annu Rev Microbiol</source> <year>2005</year>;<volume>59</volume>:<fpage>587</fpage>&#x2013;<lpage>635</lpage> <pub-id pub-id-type="doi">10.1146/annurev.micro.58.030603.123625</pub-id><pub-id pub-id-type="pmid">16153180</pub-id></citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <citation citation-type="journal"><string-name><surname>Trallero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Avellon</surname> <given-names>A</given-names></string-name>, <string-name><surname>Otero</surname> <given-names>A</given-names></string-name>, <string-name><surname>de Miguel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Alonso</surname> <given-names>M</given-names></string-name>, <string-name><surname>Perez-Brena</surname> <given-names>P</given-names></string-name> <article-title>Laboratory Network within the Polio Eradication Initiative (1998&#x2013;2003): six years of surveillance for acute flaccid paralysis in Spain</article-title><comment>[in Spanish]</comment> <source>Enferm Infecc Microbiol Clin</source> <year>2006</year>;<volume>24</volume>:<fpage>167</fpage>&#x2013;<lpage>72</lpage> <pub-id pub-id-type="doi">10.1157/13086549</pub-id><pub-id pub-id-type="pmid">16606558</pub-id></citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <citation citation-type="journal"><string-name><surname>Casas</surname> <given-names>I</given-names></string-name>, <string-name><surname>Palacios</surname> <given-names>GF</given-names></string-name>, <string-name><surname>Trallero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cisterna</surname> <given-names>D</given-names></string-name>, <string-name><surname>Freire</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Tenorio</surname> <given-names>A</given-names></string-name> <article-title>Molecular characterization of human enteroviruses in clinical samples: comparison between VP2, VP1, and RNA polymerase regions using RT nested PCR assays and direct sequencing of products.</article-title><source>J Med Virol</source> <year>2001</year>;<volume>65</volume>:<fpage>138</fpage>&#x2013;<lpage>48</lpage> <pub-id pub-id-type="doi">10.1002/jmv.2013</pub-id><pub-id pub-id-type="pmid">11505456</pub-id></citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <citation citation-type="journal"><string-name><surname>Casas</surname> <given-names>I</given-names></string-name>, <string-name><surname>Tenorio</surname> <given-names>A</given-names></string-name>, <string-name><surname>Echevarria</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Klapper</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Cleator</surname> <given-names>GM</given-names></string-name> <article-title>Detection of enteroviral RNA and specific DNA of herpesviruses by multiplex genome amplification.</article-title><source>J Virol Methods</source> <year>1997</year>;<volume>66</volume>:<fpage>39</fpage>&#x2013;<lpage>50</lpage> <pub-id pub-id-type="doi">10.1016/S0166-0934(97)00035-9</pub-id><pub-id pub-id-type="pmid">9220389</pub-id></citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <citation citation-type="journal"><string-name><surname>Yang</surname> <given-names>CF</given-names></string-name>, <string-name><surname>De</surname> <given-names>L</given-names></string-name>, <string-name><surname>Holloway</surname> <given-names>BP</given-names></string-name>, <string-name><surname>Pallansch</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Kew</surname> <given-names>OM</given-names></string-name> <article-title>Detection and identification of vaccine-related polioviruses by the polymerase chain reaction.</article-title><source>Virus Res</source> <year>1991</year>;<volume>20</volume>:<fpage>159</fpage>&#x2013;<lpage>79</lpage> <pub-id pub-id-type="doi">10.1016/0168-1702(91)90079-B</pub-id><pub-id pub-id-type="pmid">1659060</pub-id></citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <citation citation-type="journal"><string-name><surname>Cherkasova</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Yakovenko</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Rezapkin</surname> <given-names>GV</given-names></string-name>, <string-name><surname>Korotkova</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Ivanova</surname> <given-names>OE</given-names></string-name>, <string-name><surname>Eremeeva</surname> <given-names>TP</given-names></string-name>, <etal/><article-title>Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.</article-title><source>J Virol</source> <year>2005</year>;<volume>79</volume>:<fpage>1062</fpage>&#x2013;<lpage>70</lpage> <pub-id pub-id-type="doi">10.1128/JVI.79.2.1062-1070.2005</pub-id><pub-id pub-id-type="pmid">15613335</pub-id></citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <citation citation-type="journal"><string-name><surname>Karakasiliotis</surname> <given-names>I</given-names></string-name>, <string-name><surname>Paximadi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Markoulatos</surname> <given-names>P</given-names></string-name> <article-title>Evolution of a rare vaccine-derived multirecombinant poliovirus.</article-title><source>J Gen Virol</source> <year>2005</year>;<volume>86</volume>:<fpage>3137</fpage>&#x2013;<lpage>42</lpage> <pub-id pub-id-type="doi">10.1099/vir.0.80823-0</pub-id><pub-id pub-id-type="pmid">16227237</pub-id></citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <citation citation-type="journal"><string-name><surname>Korotkova</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Park</surname> <given-names>R</given-names></string-name>, <string-name><surname>Cherkasova</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Lipskaya</surname> <given-names>GY</given-names></string-name>, <string-name><surname>Chumakov</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Feldman</surname> <given-names>EV</given-names></string-name>, <etal/><article-title>Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.</article-title><source>J Virol</source> <year>2003</year>;<volume>77</volume>:<fpage>12460</fpage>&#x2013;<lpage>5</lpage> <pub-id pub-id-type="doi">10.1128/JVI.77.23.12460-12465.2003</pub-id><pub-id pub-id-type="pmid">14610170</pub-id></citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <citation citation-type="journal"><string-name><surname>Parvaneh</surname> <given-names>N</given-names></string-name>, <string-name><surname>Shahmahmoudi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tabatabai</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zahraei</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mousavi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Esteghamati</surname> <given-names>AR</given-names></string-name>, <etal/><article-title>Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency.</article-title><source>J Clin Virol</source> <year>2007</year>;<volume>39</volume>:<fpage>145</fpage>&#x2013;<lpage>8</lpage> <pub-id pub-id-type="doi">10.1016/j.jcv.2007.04.002</pub-id><pub-id pub-id-type="pmid">17509935</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
